Study of Lymphatic Dysfunction in Primary and Secondary Lymphedema (NCT05629026) | Clinical Trial Compass
RecruitingNot Applicable
Study of Lymphatic Dysfunction in Primary and Secondary Lymphedema
France60 participantsStarted 2024-02-21
Plain-language summary
Lymphedema is a disorder of the lymphatic vascular system characterized by impaired lymphatic return and swelling of the extremities and accumulation of undrained interstitial fluid/lymph that results in fibrosis and adipose tissue deposition in the affected area. It can be an inherited condition (primary lymphedema) or occurs after cancer surgery and lymph node removal (secondary lymphedema). It causes a significant morbidity and is a common disabling disease affecting more than 200 million people worldwide, however there is no curative treatment for primary or secondary lymphedema.
Who can participate
Age range18 Years – 75 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Patients in who developed primary lymphedema or secondary lymphedema after breast cancer treatment.
✓. Male and female over the age of 18 and under 75.
✓. Patient affiliated to a social security scheme in France.
✓. Patient having signed informed consent prior to inclusion in the study and prior to any specific procedure for the study.
✓. Patients with no recidive \> 3 years after cancer surgery.
✓. Patients with Body Mass Index \<35.
✓. Patient enrolled in a care pathway for the management of their lymphedema (medical and educational care).
✓. Patients wearing a compression orthosis on the limb with lymphedema.
Exclusion criteria
✕. Patients with strong suspicion or with active bacterial or fungal infection.
✕
What they're measuring
1
Number of RNA transcripts between lymphoedema limb and healthy limb